Cellectar Biosciences, Madison, reported a net loss of $2.1 million, or 49 cents a share, for the second quarter that ended June 30 compared with a net loss of $2.3 million, or $3.02 a share, for the same period last year. The results were impacted by a one-for-10 reverse stock split — or one stock for every 10 held — enacted in March. Read the full story here.
- Guest column: Unwrapping a holiday opportunity: R&D tax credits for software, tech companiesDecember 9, 2019
- Milwaukee Business Journal: Three Wisconsin venture capital funds that startups, and investors, should knowDecember 6, 2019
- InsideWis: Will clock run out on U.S., Canada, Mexico trade deal? Let’s hope notDecember 5, 2019
- WisBiz: The Show’ covers Tech Metrics, Tom Still commentary; interview with Ryan Weber and Chandra Miller FienanDecember 3, 2019
- Forbes: The 2020 ’30 under 30′ consumer technology class includes Wisconsin-based Fetch RewardsDecember 3, 2019